Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Status:
Recruiting
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the outcomes of using a JAK inhibitor prior to reduced intensity
haploidentical (Haplo) transplantation for the treatment of primary or secondary
myelofibrosis (MF). Haplo transplant has been shown to be safe and effective in patients with
leukemia and lymphoma who don't have an available sibling donor. The primary risk of using
Haplo HCT in patients with MF is graft failure as the graft failure rate has been
historically higher with Haplo HCT than with other donor sources and higher with MF patients
due to bone marrow fibrosis than in patients with other hematologic malignancies. JAK
inhibitors when used in patients with MF may decrease the size of the spleen and decrease
inflammation in the bone marrow. Therefore using a JAK inhibitor prior to Haplo transplant
has the potential to decrease graft failure in patients with MF. Haplo transplants for
patients with MF have been done successfully at multiple institutions in patients not on a
study and are currently being covered by Medicare.